Literature DB >> 28590520

Developing multicenter consortia in liver disease in Latin America: Challenges and opportunities.

Manuel Mendizabal1,2, Marcelo O Silva1,2.   

Abstract

The development of consortia has been useful for exploring challenging scenarios and uncharted territories in liver disease treatments. Several consortia already developed in the United States and Europe have become key factors in patient care decision-making processes and medical education, and they have also impacted policy makers' decisions. In Latin America, the situation is different. As a result of a combination of different factors, our region has not been able to develop networking advantages in research and education in liver diseases. Thus far, most of the initial experiences focused on the development of collaborative groups established to investigate a particular topic, which were dissolved once the questions were answered. It is the aim of this review to describe those difficulties we confront in developing multicenter liver consortia in Latin America, to identify those challenges we face, and also to describe the opportunities we have for improvement. Liver Transplantation 23 1210-1215 2017 AASLD.
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28590520     DOI: 10.1002/lt.24793

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  3 in total

Review 1.  Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement.

Authors:  Luis Antonio Díaz; Gustavo Ayares; Jorge Arnold; Francisco Idalsoaga; Oscar Corsi; Marco Arrese; Juan Pablo Arab
Journal:  Curr Treat Options Gastroenterol       Date:  2022-06-16

2.  Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges.

Authors:  Federico Piñero; Jaime Poniachik; Ezequiel Ridruejo; Marcelo Silva
Journal:  World J Gastroenterol       Date:  2018-10-07       Impact factor: 5.742

Review 3.  Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?

Authors:  Federico Piñero; Leonardo Gomes da Fonseca
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.